Investor Presentaiton
Biotech & Infotech
88
00
+85
The scale of the global medical research pipeline
has grown to 20,109 by January 2022, up 8.2%
from 12 months earlier, according to Informa
Pharma Intelligence. The number of R&D
companies in China by January 2022 has
increased by 43%, bringing its global share from
9% to 12%. Ranked second in terms of new
medicine development, China (20.8%) has been
upgrading and innovating its biotechnology
industry. One example is the new generation of
biotherapy featuring gene and cell engineering
that provides a potential solution for more
precise tumour treatment.
A combination of biotech and infotech is
bringing more value to the life science sector.
Taking "healthcare+Al" as an example, Al can cut
the time needed for new drug development and
even replace part of a doctor's work. In 2021,
research indicated that Al technology could
potentially shorten the drug development period
to 18 months, and reduce costs by 90%
compared to traditional drug development
methods.
-5,000
Global research pipeline, by Jan 2022
China Life Sciences - 2022
Number (LHS)
Growth rate (RHS)
25,000
25%
20,000
20%
15,000
15%
10,000
5,000
பளி
10%
5%
0%
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
Source: Savills Research using Informa Pharmaprojects data
-5%View entire presentation